Prosecution Insights
Last updated: April 19, 2026

Examiner: CESARE, JOSEPH DAVID

Tech Center 1600 • Art Units: 1600 1644 1675

This examiner grants 0% of resolved cases

Performance Statistics

%
Allow Rate
-60.0% vs TC avg
8
Total Applications
Interview Lift
1175
Avg Prosecution Days
Based on 0 resolved cases, 2023–2026

Rejection Statute Breakdown

17.7%
§101 Eligibility
8.8%
§102 Novelty
32.4%
§103 Obviousness
23.5%
§112 Clarity

Currently Pending Office Actions

App #TitleStatusAssignee
18268009 CLASS OF BIOMATERIALS FOR PROMOTING LARGE BLOOD VESSEL GROWTH Non-Final OA Vanderbilt University
18255503 PREVENTION AND TREATMENT OF GRAFT-VERSUS-HOST DISEASE (GVHD) Non-Final OA CITY OF HOPE
18264475 Formulations of DR5 Binding Polypeptides Non-Final OA Inhibrx Biosciences, Inc.
18274668 IL-15 FUSION PROTEINS AND METHODS OF MAKING AND USING THE SAME Non-Final OA Salubris Biotherapeutics, Inc.
18270472 FORMULATIONS OF ANTI-CD73 ANTIBODIES Non-Final OA I-MAB BIOPHARMA US LIMITED
18174127 IMMUNOASSAYS FOR DETECTING WILD TYPE HUNTINGTIN PROTEIN AND METHODS OF TREATMENT EMPLOYING SUCH IMMUNOASSAYS Non-Final OA WAVE LIFE SCIENCES LTD.
18033773 IL-2/IL-15R-BETA-GAMMA AGONIST FOR TREATING SQUAMOUS CELL CARCINOMA Non-Final OA Cytune Pharma

Facing This Examiner?

IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.

Build Your Strategy

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month